Literature DB >> 9087292

[Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].

Y Okada1, K Horikawa, M Sano.   

Abstract

Echocardiographic reports on 144 adults receiving anthracycline therapy and 18 controls were reviewed for the possible relationship between dosage and ejection fractions. The cardiotoxicity of each anthracycline drug was evaluated as follows: Pirarubicin = 0.8, Mitoxantrone = 3.4, Daunorubicin = 0.5, Aclarubicin = 0, and Epirubicin = 0.6 with Doxorubicin = 1 as a control. As a whole, the ejection fractions, which decreased subsequently compared with increasing amount of dosage, showed a remarkable decrease at the dosage level of 600 mg/m2. However, the ejection fractions differed among individual patients. It was predicted that heart failure would not develop when the ejection fractions exceeded 55%. It is desirable to stop anthracycline therapy when the ejection fractions drop to 55%.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087292

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  4 in total

1.  Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?

Authors:  Wenxi Yu; Lina Tang; Feng Lin; Yang Yao; Zan Shen
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

2.  The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies.

Authors:  Norihiko Senju; Satoshi Ikeda; Seiji Koga; Yoshiyuki Miyahara; Kunihiro Tsukasaki; Masao Tomonaga; Shigeru Kohno
Journal:  Heart Vessels       Date:  2007-11-26       Impact factor: 2.037

3.  Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy.

Authors:  Anant Khositseth; Suwadee Jirasakpisarn; Samart Pakakasama; Lulin Choubtuym; Duangrurdee Wattanasirichaigoon
Journal:  Indian J Med Paediatr Oncol       Date:  2011-01

4.  Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy.

Authors:  Naoto Okada; Takeshi Hanafusa; Takumi Sakurada; Kazuhiko Teraoka; Toshihide Kujime; Masahiro Abe; Yasuo Shinohara; Kazuyoshi Kawazoe; Kazuo Minakuchi
Journal:  J Clin Med Res       Date:  2014-05-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.